These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8015418)

  • 21. The alternative activation pathway and complement component C3 are critical for a protective immune response against Pseudomonas aeruginosa in a murine model of pneumonia.
    Mueller-Ortiz SL; Drouin SM; Wetsel RA
    Infect Immun; 2004 May; 72(5):2899-906. PubMed ID: 15102802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bismuth-thiol incorporation enhances biological activities of liposomal tobramycin against bacterial biofilm and quorum sensing molecules production by Pseudomonas aeruginosa.
    Halwani M; Hebert S; Suntres ZE; Lafrenie RM; Azghani AO; Omri A
    Int J Pharm; 2009 May; 373(1-2):141-6. PubMed ID: 19429299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complement activation in Staphylococcus aureus bacteraemia.
    Hallett AF; Cooper R
    Clin Exp Immunol; 1980 May; 40(2):306-11. PubMed ID: 6904257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pseudomonas aeruginosa alkaline protease blocks complement activation via the classical and lectin pathways.
    Laarman AJ; Bardoel BW; Ruyken M; Fernie J; Milder FJ; van Strijp JA; Rooijakkers SH
    J Immunol; 2012 Jan; 188(1):386-93. PubMed ID: 22131330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients.
    Murray TS; Egan M; Kazmierczak BI
    Curr Opin Pediatr; 2007 Feb; 19(1):83-8. PubMed ID: 17224667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased mutability of Pseudomonas aeruginosa in biofilms.
    Driffield K; Miller K; Bostock JM; O'Neill AJ; Chopra I
    J Antimicrob Chemother; 2008 May; 61(5):1053-6. PubMed ID: 18256114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complement activation by Proteus mirabilis negatively charged lipopolysaccharides.
    Kaca W; Literacka E; Sjöholm AG; Weintraub A
    J Endotoxin Res; 2000; 6(3):223-34. PubMed ID: 11052177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation.
    Drenkard E; Ausubel FM
    Nature; 2002 Apr; 416(6882):740-3. PubMed ID: 11961556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of the alternative pathway of human complement by the extracellular slime glycolipoprotein of Pseudomonas aeruginosa.
    Lambris J; Papamichail M; Ioannidis C; Dimitracopoulos G
    J Infect Dis; 1982 Jan; 145(1):78-82. PubMed ID: 6798132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Haemophilus influenzae type b lipopolysaccharide on complement activation and polymorphonuclear leukocyte function.
    Inzana TJ; Tosi MF; Kaplan SL; Anderson DC; Mason EO; Williams RP
    Pediatr Res; 1987 Dec; 22(6):659-66. PubMed ID: 3324033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pseudomonas aeruginosa and Burkholderia cenocepacia infections in patients affected by cystic fibrosis: serum resistance and antibody response.
    Savoia D; Deplano C; Zucca M
    Immunol Invest; 2008; 37(1):19-27. PubMed ID: 18214797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complement activation in platelet concentrates is surface-dependent and modulated by the platelets.
    Gyongyossy-Issa MI; McLeod E; Devine DV
    J Lab Clin Med; 1994 Jun; 123(6):859-68. PubMed ID: 8201264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Salt-sensitivity of complement (C)-consumption induced by anticomplementary antigens and antigen/antibody complexes.
    Gancevici G; Popescu C; Toporan M
    Arch Roum Pathol Exp Microbiol; 1982; 41(3):239-50. PubMed ID: 6818928
    [No Abstract]   [Full Text] [Related]  

  • 34. Mucin-Pseudomonas aeruginosa interactions promote biofilm formation and antibiotic resistance.
    Landry RM; An D; Hupp JT; Singh PK; Parsek MR
    Mol Microbiol; 2006 Jan; 59(1):142-51. PubMed ID: 16359324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity in patients with cystic fibrosis.
    Rogan MP; Taggart CC; Greene CM; Murphy PG; O'Neill SJ; McElvaney NG
    J Infect Dis; 2004 Oct; 190(7):1245-53. PubMed ID: 15346334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complement activation during CAPD.
    Young GA; Kendall S; Brownjohn AM
    Nephrol Dial Transplant; 1993; 8(12):1372-5. PubMed ID: 8159307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia. A new prophylactic principle.
    Johansen HK; Cryz SJ; Hougen HP; Moser C; Høiby N
    Behring Inst Mitt; 1997 Feb; (98):269-73. PubMed ID: 9382750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibitory efficacy of various antibiotics on matrix and viable mass of Staphylococcus aureus and Pseudomonas aeruginosa biofilms.
    Toté K; Berghe DV; Deschacht M; de Wit K; Maes L; Cos P
    Int J Antimicrob Agents; 2009 Jun; 33(6):525-31. PubMed ID: 19179053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delivery of photosensitisers and light through mucus: investigations into the potential use of photodynamic therapy for treatment of Pseudomonas aeruginosa cystic fibrosis pulmonary infection.
    Donnelly RF; McCarron PA; Cassidy CM; Elborn JS; Tunney MM
    J Control Release; 2007 Feb; 117(2):217-26. PubMed ID: 17196290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Infections with Pseudomonas aeruginosa in patients with cystic fibrosis.
    Tümmler B; Bosshammer J; Breitenstein S; Brockhausen I; Gudowius P; Herrmann C; Herrmann S; Heuer T; Kubesch P; Mekus F; Römling U; Schmidt KD; Spangenberg C; Walter S
    Behring Inst Mitt; 1997 Feb; (98):249-55. PubMed ID: 9382747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.